A quantitative exploration of symptoms in COVID-19 patients: an observational cohort study

Qu, Gaojing; Chen, Junwen; Huang, Guoxin; Zhang, Meiling; Yu, Hui; Zhu, Haoming; Chen, Lei; Wang, Dengru; Pei, Bin

doi:10.7150/ijms.53596

Cited by 8 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An association among chest distress, dyspnea, and shortness of breath was related to increased mortality. 26 In our research, dyspnea was the most common symptom associated with SP-SPM (93.3%), but it was also present in a high percentage of the COVID-19 control group (50.7%). Chest pain was found to be the most specific symptom in the SP-SPM case group, regardless of COVID-19 condition: present in 60% of negative vs 43.3% of positive cases.…”

supporting

confidence: 45%

See 1 more Smart Citation

Risk Factors, Characteristics, and Outcome in Non-Ventilated Patients with Spontaneous Pneumothorax or Pneumomediastinum Associated with SARS-CoV-2 Infection

Marza¹,

Petrică²,

Lungeanu³

et al. 2022

IJGM

View full text Add to dashboard Cite

Background and Objectives: Spontaneous pneumothorax (SP) and spontaneous pneumomediastinum (SPM) have frequently been cited as complications associated with coronavirus disease 2019 (COVID-19) pneumonia, with especially poor prognosis in mechanically ventilated patients. The current literature is controversial regarding the potential risk factors for developing SP or SPM (SP-SPM) in non-ventilated COVID-19 patients. Our research addressed a twofold objective: (a) to investigate the characteristics of patients with SP-SPM (both with and without COVID-19) and compare them to patients with sole COVID-19; (b) to quantify the risk of in-hospital mortality associated with SP-SPM and COVID-19. Patients and Methods: A retrospective case-control study was conducted in the emergency departments (ED) of two tertiary hospitals in Timisoara, Romania, over one year (1st April 2020-31st March 2021; 64,845 records in total) and 70 cases of SP-SPM were identified (both SARS-CoV-2 positives and negatives). The control group comprised COVID-19 patients with no SP-SPM, included at a 2:1 ratio. Logistic regression was employed to quantify the in-hospital mortality risk associated with age, SP-SPM, and COVID-19. Results: SP-SPM and COVID-19 were connected with prolonged hospitalization, a higher percentage of intensive care admission, and a higher mortality. SP-SPM increased the odds of death by almost four times in patients of the same age, gender, smoking status, and SARS-CoV-2 infection: OR = 3.758, 95% CI (1.443-9.792). Each additional year of age added 9.4% to the mortality risk: OR = 1.094, 95% CI (1.054-1.135). Conclusion:ED physicians should acknowledge these potential risks when attending COVID-19 patients with SP-SPM.

show abstract

supporting

confidence: 45%

“…In an observational cohort study by Qu et al, 26 dyspnea was found as a marker for critical forms of COVID-19. An association among chest distress, dyspnea, and shortness of breath was related to increased mortality.…”

mentioning

confidence: 97%

Risk Factors, Characteristics, and Outcome in Non-Ventilated Patients with Spontaneous Pneumothorax or Pneumomediastinum Associated with SARS-CoV-2 Infection

Marza¹,

Petrică²,

Lungeanu³

et al. 2022

IJGM

View full text Add to dashboard Cite

show abstract

“…According to statistics, between 60 and 70 percent of women feel dyspnea and shortness of breath with exertion, with occurrence rates rising in the second trimester [27]. Diagnosing lung disease during pregnancy is challenging due to these physiologic changes.…”

Section: Covid-19 In Pregnancymentioning

confidence: 99%

Vaccination of pregnant women against COVID-19 under martial law: a narrative review

2022

FEM

View full text Add to dashboard Cite

Background: Global vaccination programs against the coronavirus illness of 2019 (COVID-19) have been established as the primary measure to minimise and control the effects of the COVID-19 pandemic. During pregnancy, it is assumed that the expectant mother and her fetus are both in danger from the possibility of a viral infection. Aim: to evaluate the safety and effectiveness of vaccination against COVID-19 for pregnant women and determine the impact of vaccination on pregnancy outcomes. Methods: In this review, English studies from common databases such as Pubmed/MEDLINE, Web of Science, Scopus, and the Cochrane Library with the keywords "Vaccination," "pregnancy," and "pregnant women," combined with keywords, involving "COVID-19," were involved. The end date for this review is March 2022. Scientific novelty: The main objective of this paper is to evaluate the effect of vaccination of pregnant women against COVID-19. Even though many studies assessed the efficacy of vaccination against COVID-19, most failed to determine the safety and effectiveness of COVID-19 vaccination for immunocompromised patients, especially pregnant women. Additionally, the impact of COVID-19 vaccination on neonatal outcomes was evaluated. The practical significance of the obtained result: Concerns have also been raised about potential risks associated with vaccination during pregnancy or breastfeeding. Given these uncertainties, it is important for healthcare providers to carefully consider the risks and benefits of COVID-19 vaccination for pregnant women and their babies. Further research is needed to better understand the effects of vaccination on perinatal outcomes and to inform clinical decision-making around vaccine use in this population. Conclusion: The COVID-19 vaccination is a safe and effective way to protect pregnant women from the virus. The benefits of getting vaccinated outweigh the risks, as pregnant women are at an increased risk of severe illness and complications from COVID-19. The Centers for Disease Control and Prevention (CDC) recommends that pregnant women get vaccinated, and many healthcare providers also recommend it. However, it is important for pregnant women to discuss their individual situation with their healthcare provider before making a decision about vaccination. Overall, getting vaccinated can help to protect both the mother and her unborn child from COVID-19. Background: Global vaccination programs against the coronavirus illness of 2019 (COVID-19) have been established as the primary measure to minimise and control the effects of the COVID-19 pandemic. During pregnancy, it is assumed that the expectant mother and her fetus are both in danger from the possibility of a viral infection. Aim: to evaluate the safety and effectiveness of vaccination against COVID-19 for pregnant women and determine the impact of vaccination on pregnancy outcomes. Methods: In this review, English studies from common databases such as Pubmed/MEDLINE, Web of Science, Scopus, and the Cochrane Library with the keywords "Vaccination," "pregnancy," and "pregnant women," combined with keywords, involving "COVID-19," were involved. The end date for this review is March 2022. Scientific novelty: The main objective of this paper is to evaluate the effect of vaccination of pregnant women against COVID-19. Even though many studies assessed the efficacy of vaccination against COVID-19, most failed to determine the safety and effectiveness of COVID-19 vaccination for immunocompromised patients, especially pregnant women. Additionally, the impact of COVID-19 vaccination on neonatal outcomes was evaluated. The practical significance of the obtained result: Concerns have also been raised about potential risks associated with vaccination during pregnancy or breastfeeding. Given these uncertainties, it is important for healthcare providers to carefully consider the risks and benefits of COVID-19 vaccination for pregnant women and their babies. Further research is needed to better understand the effects of vaccination on perinatal outcomes and to inform clinical decision-making around vaccine use in this population. Conclusion: The COVID-19 vaccination is a safe and effective way to protect pregnant women from the virus. The benefits of getting vaccinated outweigh the risks, as pregnant women are at an increased risk of severe illness and complications from COVID-19. The Centers for Disease Control and Prevention (CDC) recommends that pregnant women get vaccinated, and many healthcare providers also recommend it. However, it is important for pregnant women to discuss their individual situation with their healthcare provider before making a decision about vaccination. Overall, getting vaccinated can help to protect both the mother and her unborn child from COVID-19.

show abstract

“…COVID-19 is still spreading in many countries and regions around the world and poses a serious threat to people's health. COVID-19 patients could suffer fever, cough, dyspnea, diarrhea, and other symptoms [4][5][6], involving various organs such as the lung, gastrointestinal tract, heart, liver, kidney, and brain [7][8][9], which causes changes in the composition or content of blood cells, electrolytes, enzymes, urine, and other body fluids. Laboratory tests could objectively reflect the changes in the internal environment and the functions of organs, which plays an important role in understanding the pathological processes of COVID-19 and improving the level of diagnosis and therapy in COVID- 19.…”

Section: Introductionmentioning

confidence: 99%

A comprehensive analysis of systematically screened laboratory tests: based on a COVID-19 cohort

Chen

Huang

et al. 2023

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The study aimed at screening indicators with differential diagnosis values and investigating the characteristics of laboratory tests in COVID-19 patients. Methodology: All the laboratory tests from COVID-19 patients and non-COVID-19 patients in this cohort were included. Test values from the groups during the course, days 1-7, and days 8-14 were analyzed. Mann-Whitney U test, univariate logistic regression analysis, and multivariate regression analysis were performed. Regression models were established to verify the diagnostic performance of indicators. Results: 302 laboratory tests were included in this cohort, and 115 indicators were analyzed; the values of 61 indicators had significant differences (p < 0.05) between groups, and 23 indicators were independent risk factors of COVID-19. During days 1-7, the values of 40 indicators had significant differences (p < 0.05) between groups, while 20 indicators were independent risk factors of COVID-19. During days 8-14, the values of 45 indicators had significant differences (p < 0.05) between groups, and 23 indicators were independent risk factors of COVID-19. About 10, 12, and 12 indicators showed significant differences (p < 0.05) in multivariate regression analysis in different courses respectively, and the diagnostic performance of the model from them was 74.9%, 80.3%, and 80.8% separately. Conclusions: The indicators obtained through systematic screening have preferable differential diagnosis values. Compared with non-COVID-19 patients, the screened indicators indicated that COVID-19 patients had more severe inflammatory responses, organ damage, electrolyte and metabolism disturbance, and coagulation disorders. This screening approach could find valuable indicators from a large number of laboratory test indicators.

show abstract

A quantitative exploration of symptoms in COVID-19 patients: an observational cohort study

Cited by 8 publications

References 34 publications

Risk Factors, Characteristics, and Outcome in Non-Ventilated Patients with Spontaneous Pneumothorax or Pneumomediastinum Associated with SARS-CoV-2 Infection

Risk Factors, Characteristics, and Outcome in Non-Ventilated Patients with Spontaneous Pneumothorax or Pneumomediastinum Associated with SARS-CoV-2 Infection

Vaccination of pregnant women against COVID-19 under martial law: a narrative review

A comprehensive analysis of systematically screened laboratory tests: based on a COVID-19 cohort

Contact Info

Product

Resources

About